Liver transplantation for pediatric metabolic disease

George Mazariegos, Benjamin Shneider, Barbara Burton, Ira J. Fox, Nedim Hadzic, Priya Kishnani, D. Holmes Morton, Sara Mcintire, Ronald J. Sokol, Marshall Summar, Desiree White, Vincent Chavanon, Jerry Vockley*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

85 Scopus citations


Liver transplantation (LTx) was initially developed as a therapy for liver diseases known to be associated with a high risk of near-term mortality but is based upon a different set of paradigms for inborn metabolic diseases. As overall outcomes for the procedure have improved, LTx has evolved into an attractive approach for a growing number of metabolic diseases in a variety of clinical situations. No longer simply life-saving, the procedure can lead to a better quality of life even if not all symptoms of the primary disorder are eliminated. Juggling the risk-benefit ratio thus has become more complicated as the list of potential disorders amenable to treatment with LTx has increased. This review summarizes presentations from a recent conference on metabolic liver transplantation held at the Children's Hospital of Pittsburgh of UPMC on the role of liver or hepatocyte transplantation in the treatment of metabolic liver disease.

Original languageEnglish (US)
Pages (from-to)418-427
Number of pages10
JournalMolecular Genetics and Metabolism
Issue number4
StatePublished - Apr 2014


  • Amino aciduria
  • Hepatocyte transplant
  • Inborn errors of metabolism
  • Liver failure
  • Liver transplant
  • Organic acidemia

ASJC Scopus subject areas

  • Genetics
  • Endocrinology
  • Molecular Biology
  • Biochemistry
  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'Liver transplantation for pediatric metabolic disease'. Together they form a unique fingerprint.

Cite this